Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

 Professor Tiejun Gong: Striving for Excellence, 2024 CSCO Guidelines on Malignant Hematology with a Focus on Leukemia | 2024 CSCO Guidelines Conference

The 2024 China Clinical Oncology Society (CSCO) Guidelines Conference was held in Jinan on April 26-27, 2024. As always, the conference updated and released multiple CSCO cancer treatment guidelines. Professor Tiejun Gong, Deputy Director of the Harbin Institute of Hematologic Oncology, gave an insightful interpretation of the leukemia section in the "2024 CSCO Guidelines on Malignant Hematology." After the conference, "Oncology Frontier - Hematology Frontier" invited Professor Gong to introduce the characteristics and updates in leukemia treatment in the 2024 CSCO Malignant Hematology Guidelines, discuss current challenges in leukemia treatment, and express his views on potential improvements.
EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

EBMT 2024 | Dr. Li Gao：The MRD status on day 7 and CD4 count at 1 month after CAR-T therapy are prognostic indicators in CAR-T treatments

From April 14 to 17, 2024, the 50th Annual Congress of the European Society for Blood and Marrow Transplantation (EBMT) was held with great ceremony in Glasgow, UK. The conference focused on the latest advancements in stem cell transplantation and cell therapy, advancing patients with hematological diseases towards better clinical prognoses. At this congress, Dr. Li Gao from Soochow University Affiliated Children's Hospital reported on a study.
2024 CUDA Yanqi Lake Conference | Professor Xuesong Li: Optimizing Prostate Cancer Management to Safeguard Men’s Lives

2024 CUDA Yanqi Lake Conference | Professor Xuesong Li: Optimizing Prostate Cancer Management to Safeguard Men’s Lives

The "4th Chinese Medical Association Urology Surgeons Branch Yanqi Lake Conference (2024)" was successfully held in Beijing from April 13th to 14th. The conference not only focused on clinical practices in urology surgery but also discussed cutting-edge developments and important topics in the industry. At the conference, Professor Xuesong Li from Peking University First Hospital shared insights on "Optimizing Prostate Cancer Management to Safeguard Men's Lives." "Oncology Frontier - Urology News" has specially compiled relevant content for readers.
2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

2024 CSCO Guideline Symposium: Professor Tiejun Gong: “Updates to the CSCO Guidelines for Malignant Hematologic Diseases” Drive Clinical Diagnosis

With the development of targeted therapy and immunotherapy, the treatment options for malignant hematologic diseases continue to expand. The "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Malignant Hematologic Diseases (2024)" has once again been updated. "Oncology Watch" specially interviewed one of the guideline's authors, Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology, to provide in-depth explanations on the highlights of the guideline updates, their impact on clinical practice, and the implementation of the guidelines.
Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

Professor Qing Cao’s Commentary: Emerging Staphylococcus Threatens Newborn Health | ESCMID Global 2024

In low- and middle-income countries, the health of newborns faces numerous challenges, with neonatal sepsis being a particularly grave concern. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: O0158) focused on the threat posed by Coagulase-Negative Staphylococci (CoNS) to newborn health. These bacteria, increasingly reported in low- and middle-income countries, exhibit insensitivity to multiple commonly used antibiotics, complicating treatment. Professor Qing Cao from the Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine, provides a detailed commentary on this study, sharing her professional insights and recommendations.
EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

EBMT Distinguished Interview | Optimizing Induction Therapy Before ASCT: From Past to Future

Induction therapies with high remission rates, combined with high-dose chemotherapy and autologous stem cell transplantation (ASCT), have significantly improved the prognosis for multiple myeloma (MM) patients. Despite this, patients still inevitably experience disease progression or relapse. One of the key goals in this research field is how to maintain remission in patients after induction therapy and ASCT. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK, from April 14 to 17, 2024. The conference focused on the latest advancements in stem cell transplantation and cellular therapy, driving better clinical outcomes for patients with hematological diseases and cancers. At this conference, Professor Jean-Luc Harousseau, Chairman of the French National Health Authority and Director of the René Gauducheau Cancer Center at the University of Nantes, delivered an insightful presentation on optimizing induction therapy strategies for multiple myeloma patients before ASCT. "Hematology Frontier" invited Professor Harousseau to share his insights on continuously optimizing pre-ASCT induction therapy for multiple myeloma patients.
Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

Professor Wei Yu Shares Research Progress in NMIBC Treatment | EAU24 Expert Commentary

Transurethral resection of bladder tumors (TURBt) is the conventional treatment for non-muscle-invasive bladder cancer (NMIBC). Patients are stratified into low, intermediate, high, and very high risk categories, with different postoperative bladder instillation treatments and follow-up monitoring strategies for different risk patients. Several advancements in NMIBC research were presented at the recent EAU conference, and "Oncology Frontier-Urology Frontier" invited Professor Wei Yu from Peking University First Hospital to share related research findings.
 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

 Recent Advances in the Treatment of Advanced Urothelial Carcinoma: Insights from Dr. Jens Bedke

Platinum-based combination chemotherapy remains the cornerstone of treatment for advanced urothelial carcinoma (UC), but it still falls short of meeting long-term survival needs. At the 39th Annual Congress of the European Association of Urology (EAU24) held in Paris, France, Dr. Jens Bedke, from Klinikum Stuttgart Katharinen Hospital, shared the results of the EV-302/KEYNOTE-A39 study. Urology Frontier had the privilege of inviting renowned expert Dr. Jens Bedke to discuss the current status of immunotherapy, recent major advances in clinical trials, and future directions in UC treatment.
Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

Professor Vasileios Sakalis on the Value of Artificial Intelligence in the Diagnosis and Treatment of Urological Tumors

Artificial Intelligence (AI) is transforming the diagnostic and treatment approaches for urological tumors, especially with significant advancements in intelligent imaging and pathology, potentially becoming an indispensable tool for clinicians. Dr. Vasileios Sakalis, a urologist from the Hippokrateion General Hospital of Thessaloniki, Greece, presented a comprehensive review on the application of AI in urological tumors at the conference. During an on-site interview with "Oncology Frontier-Urology Frontier," he shared further insights on the applications of AI.
2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

2024 CUDA Yanqi Lake Conference | Professor Xiongjun Ye Shares Recent Breakthroughs in Renal Cell Carcinoma Treatment

The ASCO-GU, a premier academic conference in urologic oncology, at the beginning of the year sparked academic enthusiasm in 2024, receiving over 140 abstracts related to renal cell carcinoma (RCC). Professor Xiongjun Ye from the Chinese Academy of Medical Sciences Cancer Hospital presented a report on the significant progress in RCC treatment from the ASCO-GU at the 4th Yanqi Lake Conference of the Chinese Medical Association Urology Surgery Branch, summarizing the essence for all to appreciate.